Mengmeng Wang

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Unveiling the hidden risks of nanomedicine-based drug delivery: a comparative evaluation of drug safety profiles of liposomal irinotecan and conventional irinotecan.

Unveiling the hidden risks of nanomedicine-based drug delivery: a comparative evaluation of drug safety profiles of liposomal irinotecan and conventional irinotecan.

Journal: Nanotoxicology

Published: February 17, 2026

HBV infection occurred despite apparently adequate prophylaxis in a lung transplant recipient.

HBV infection occurred despite apparently adequate prophylaxis in a lung transplant recipient.

Journal: Journal of hepatology

Published: February 13, 2026

Comparative efficacy and safety of four long-acting granulocyte colony-stimulating factors for primary prophylaxis in patients with breast cancer: a prospective observational cohort study in China.

Comparative efficacy and safety of four long-acting granulocyte colony-stimulating factors for primary prophylaxis in patients with breast cancer: a prospective observational cohort study in China.

Journal: EClinicalMedicine

Published: January 25, 2026

Application of Droplet Digital PCR in Sputum Samples in Myasthenia Gravis Patients with Pneumonia.

Application of Droplet Digital PCR in Sputum Samples in Myasthenia Gravis Patients with Pneumonia.

Journal: Infection and drug resistance

Published: December 15, 2025

Distinct safety profiles of liposomal and conventional irinotecan: insights from clinical experience and real-world data.

Distinct safety profiles of liposomal and conventional irinotecan: insights from clinical experience and real-world data.

Journal: Frontiers in pharmacology

Published: November 13, 2025

Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia.

Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia.

Journal: Frontiers in oncology

Published: May 29, 2025

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis.

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis.

Journal: Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Published: May 23, 2025

Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis.

Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis.

Journal: Frontiers in oncology

Published: May 04, 2025

Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.

Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 09, 2024

Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study.

Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study.

Journal: Clinical Medicine Insights. Oncology

Published: June 14, 2024

Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system.

Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system.

Journal: Expert opinion on drug safety

Published: March 10, 2023

Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study.

Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study.

Journal: Journal of clinical pharmacy and therapeutics

Published: August 31, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026